You are here

Article Text

Article menu
Download PDFPDF
Correspondence response
Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis
  1. Jean Yves Reginster1,2,3
  1. 1 Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
  2. 2 Bioethics and Societal Medicine, University of Liege, Liege, Belgium
  3. 3 WHO Collaborating Center for Public Health aspects of muskulo-skeletal health and aging, University of Liege, Liege, Belgium
  1. Correspondence to Professor Jean Yves Reginster, Public Health, Epidemiology and Health Economics, WHO Collaborating Center for Public Health aspects of muskulo-skeletal health and aging, University of Liege-4020, Liege, Belgium; jyreginster{at}ulg.ac.be

https://doi.org/10.1136/annrheumdis-2017-212460

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We are very grateful to Professor Lee1 for his senseful comments regarding our recently published paper showing that pharmaceutical-grade chondroitin sulfate is superior to placebo and similar to celecoxib in reducing pain and improving function in patients with knee osteoarthritis.2 We fully …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles